Partnering With Health Systems: Essential Tips For CGT Commercialization

Transitioning Cell and Gene Therapies (CGT) from the controlled environment of clinical trials to a commercial launch often reveals significant operational gaps. Processes designed for research rarely survive the demands of routine hospital care without adaptation. To ensure patient access, manufacturers must collaborate with health systems early, prioritizing scalability over the bespoke nature of trial protocols.

This involves more than just product delivery; it requires aligning with the entire medication-use process, from coordinating payment schedules to mitigate cash flow risks to navigating complex site authorization procedures. Health systems need partners that understand the nuances of internal hospital logistics, accreditation, and staffing. By validating commercial feasibility during the trial phase and conducting preparatory site visits, manufacturers can identify and resolve barriers before launch. Read the full article for direct insights from health system pharmacy leaders on optimizing this critical transition.